Cargando…

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy

MHC class II expression is a hallmark of professional antigen-presenting cells and key to the induction of CD4+ T helper cells. We found that these molecules are ectopically expressed on tumor cells in a large proportion of patients with pancreatic ductal adenocarcinoma (PDAC) and on several PDAC ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baleeiro, Renato B., Bouwens, Christian J., Liu, Peng, Di Gioia, Carmela, Dunmall, Louisa S. Chard, Nagano, Ai, Gangeswaran, Rathistevy, Chelala, Claude, Kocher, Hemant M., Lemoine, Nicholas R., Wang, Yaohe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154752/ https://www.ncbi.nlm.nih.gov/pubmed/35655709 http://dx.doi.org/10.1080/2162402X.2022.2080329

Ejemplares similares

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
por: Brito Baleeiro, Renato, et al.
Publicado: (2023)

Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy
por: Baleeiro, Renato B., et al.
Publicado: (2022)

A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer
por: Marelli, Giulia, et al.
Publicado: (2021)

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
por: Jia, Yangyang, et al.
Publicado: (2023)

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
por: Wang, Lihong, et al.
Publicado: (2022)

Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers
por: Lan, Tianfeng, et al.
Publicado: (2021)

Natural products targeting glycolysis in cancer
por: Zhao, Yuanyuan, et al.
Publicado: (2022)

Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus
por: Ferguson, Mark S., et al.
Publicado: (2020)

An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition
por: Sun, Yijie, et al.
Publicado: (2022)

A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma
por: Zhang, Zifang, et al.
Publicado: (2020)

Characterization of the Intra-tumoral B Cell Immunoglobulin Repertoire Is of Prognostic Value for Esophageal Squamous Cell Carcinoma
por: Wang, Zhizhong, et al.
Publicado: (2022)

A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer
por: Wang, Na, et al.
Publicado: (2020)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Direct Activation of Human Dendritic Cells by Particle-Bound but Not Soluble MHC Class II Ligand
por: Baleeiro, Renato B., et al.
Publicado: (2013)

Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients
por: Zhang, Na, et al.
Publicado: (2022)

Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene
por: Cao, Dujuan, et al.
Publicado: (2022)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
por: Zhou, Wenping, et al.
Publicado: (2023)

Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer
por: Lan, Tianfeng, et al.
Publicado: (2022)

Syrian Hamster as an Animal Model for the Study on Infectious Diseases
por: Miao, Jinxin, et al.
Publicado: (2019)

A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9
por: Yuan, Ming, et al.
Publicado: (2015)

Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders
por: Fridkis-Hareli, Masha
Publicado: (2013)

Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
por: Thibodeau, Jacques, et al.
Publicado: (2012)

The urgent need to recover MHC class I in cancers for effective immunotherapy
por: Garrido, Federico, et al.
Publicado: (2016)

Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation
por: Harada, T, et al.
Publicado: (2007)

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
por: Cornel, Annelisa M., et al.
Publicado: (2020)

MHC class I multimers
por: Sun, Mei-Yi, et al.
Publicado: (2001)

Structural Properties of MHC Class II Ligands, Implications for the Prediction of MHC Class II Epitopes
por: Jørgensen, Kasper Winther, et al.
Publicado: (2010)

A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws
por: Gadaleta, Emanuela, et al.
Publicado: (2011)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Ligation of MHC Class II Induces PKC-Dependent Clathrin-Mediated Endocytosis of MHC Class II
por: Masaki, Kento, et al.
Publicado: (2020)

Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides
por: Besser, Hanan, et al.
Publicado: (2019)

Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy
por: Rossi, Renato E, et al.
Publicado: (2010)

Superantigen and class II MHC molecules.
por: Kim, J.
Publicado: (1995)

Organizing MHC Class II Presentation
por: Fooksman, David R.
Publicado: (2014)

MHC Class II Presentation in Autoimmunity
por: Ishina, Irina A., et al.
Publicado: (2023)

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
por: Reits, Eric A., et al.
Publicado: (2006)

The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
por: Shukla, Akhil, et al.
Publicado: (2021)

Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation
por: Wieczorek, Marek, et al.
Publicado: (2017)

The Pancreatic Expression Database: 2018 update
por: Marzec, Jacek, et al.
Publicado: (2018)

SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine
por: Dayem Ullah, Abu Z, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oreq5lnb3c7ad4g3k9fu69j2em